A carregar...
Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit. Phase I studies demonstrated 5 mg twice daily as the recommended starting dose with notable effects seen in renal cell carcinoma, an observation confirmed in...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4334173/ https://ncbi.nlm.nih.gov/pubmed/25709499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S74202 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|